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Abstract 
Background: Accumulation of epicardial fat (EF) is associated with increased cardio-metabolic risks and coronary 
events, independently of traditional cardiovascular risk factors. Therefore, the reduction of EF volume (EFV) may be 
associated with reduced cardio-metabolic risks and future cardiovascular events. Sodium-glucose co-transporter-2 
(SGLT2) inhibitors reduce body fat including visceral fat and cardiovascular events in patients with type 2 diabetes. 
However, it has still been unknown whether SGLT2 inhibitors can reduce EFV.
Methods: Type 2 diabetic patients with HbA1c 6.5–9.0% and body mass index (BMI, kg/m2) ≥25.0 were enrolled in 
this single arm pilot study. Participants were administered luseogliflozin 2.5 mg daily and the dosage was tolerated to 
be increased up to 5.0 mg daily. EFV [median (interquartile range), cm3] was measured by magnetic resonance imag-
ing. Primary endpoint was the decrease in EFV at 12 weeks. Visceral fat area (VFA, cm2) and liver attenuation index (LAI) 
measured by the abdominal computed tomography, and skeletal muscle index (SMI) and body fat (%) measured by 
the whole body dual-energy X-ray absorptiometry were also determined at baseline and at 12 weeks.
Results: Nineteen patients (mean age: 55 ± 12 years; 26% female) completed this study. Luseogliflozin treatment 
significantly reduced EFV at 12 weeks [117 (96–136) to 111 (88–134), p = 0.048]. The body weight, BMI, systolic and 
diastolic blood pressure, HbA1c, fasting plasma glucose, insulin, homeostasis model assessment-insulin resistance 
(HOMA-IR), triglycerides, SMI, and body fat were significantly reduced by luseogliflozin at 12 weeks. The reduction of 
EFV was significantly correlated with the reduction of C-reactive protein (r = 0.493, p = 0.019). Neither VFA nor LAI 
were significantly reduced by the luseogliflozin treatment. No severe adverse events were observed.
Conclusions: Our data suggest that luseogliflozin could reduce the EFV in parallel with the improvement of systemic 
micro-inflammation and the reduction of body weight in Japanese patients with type 2 diabetes. The reduction of 
muscle mass after the administration of SGLT2 inhibitors may require a particular attention.
Trial registration umin.ac.jp, UMIN000019072
Keywords: Luseogiflozin, Epicardial fat, Type 2 diabetes
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Cardiovascular Diabetology
*Correspondence:  bouchi.mem@tmd.ac.jp 
1 Department of Molecular Endocrinology and Metabolism, Graduate 
School of Medical and Dental Sciences, Tokyo Medical and Dental 
University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
Full list of author information is available at the end of the article
Page 2 of 9Bouchi et al. Cardiovasc Diabetol  (2017) 16:32 
Background
Epicardial fat (EF), the local adipose tissue surround-
ing the heart, located between the myocardium and the 
visceral pericardium, has been recognized as one of the 
phenotypes of ectopic fat accumulation [1, 2]. EF accu-
mulation is thought to be involved in the progression of 
coronary atherosclerosis, through the secretion of bio-
active inflammatory cytokines and adipokines [3–6]. 
It has recently been reported that EF volume (EFV) is 
associated with non-calcified coronary plaque [7–9]. In 
addition, EFV is associated with cardio-metabolic risks 
including insulin resistance [10, 11] and type 2 diabetes 
[12] and both fatal and nonfatal coronary events, inde-
pendently of traditional cardiovascular risk factors [9]. It 
is therefore conceivable that the reduction of EFV could 
be associated with reduced cardio-metabolic risks and 
future cardiovascular events.
EFV was reported to be correlated with obesity [13]. 
In addition to obesity, diabetes was also associated with 
EFV [14]. Therefore, obese patients with type 2 diabetes 
have an extremely high risk for developing ectopic adi-
posity [15]. In diabetic patients, EFV was associated with 
dyslipidemia [16] and endothelial dysfunction [17], com-
pared to non-diabetic subjects. Furthermore, a recent 
study demonstrated that diabetes, even in the absence of 
obesity, is associated with an increased myocardial tri-
glyceride content, increased hepatic triglyceride content, 
and impaired myocardial energetics [18]. The authors 
also demonstrate that the degree of both hepatic and 
epicardial fat accumulations are associated with a car-
diac contractile dysfunction in the patients with diabetes. 
Give these findings, the evaluation of EFV may be impor-
tant to predict future coronary events, especially in obese 
patients with diabetes.
Sodium-glucose co-transporter-2 (SGLT2) inhibi-
tors lower the blood glucose level in patients with type 
2 diabetes by decreasing the renal glucose reabsorption 
[19] and its improvement of glycemic control is parallel 
with the reduction of body weight and visceral fat [20, 
21]. Recently, it has been revealed from the EMPA-REG 
outcome study that empagliflozin significantly reduces 
the composite outcome of death from cardiovascular 
causes, nonfatal myocardial infarction, or nonfatal stroke 
(3-point MACE) in patients with type 2 diabetes and 
high cardiovascular risks [22]. Although it has still been 
elusive which mechanisms are involved in the favora-
ble effects of empagliflozin on cardiovascular events, it 
is expected that the reduction of EFV in addition to the 
reduction of body weight, may be associated with the 
improvement of CV outcomes. Therefore, we hypoth-
esized that the administration of SGLT2 inhibitors could 
reduce the EFV in patients with type 2 diabetes, and its 
reduction could be correlated with the changes in insu-
lin sensitivity, body fat, and secretion of adipokines or 
cytokines, all of which are associated with cardiovascular 
events. A pooled analysis of four 52-week Phase III trials 
of luseogliflozin in Japanese patients with type 2 diabetes 
has recently showed that luseogliflozin is especially ben-
eficial in patients with a higher body mass index (BMI) 
in terms of metabolic abnormalities, including obe-
sity, hyperinsulinemia, and hypertension [23]. It is also 
reported that luseogliflozin can reduce a waist circum-
ference, a surrogate marker for visceral adiposity, with a 
significant reduction of HbA1c among Japanese patients 
with type 2 diabetes [24]. Given these findings, we have 
focused on the potential of luseogliflozin to improve the 
abnormal regional fat distribution, especially an excessive 
accumulation of EFV and we conducted this small-scale 
pilot study to investigate whether luseogliflozin could 
reduce the EFV in Japanese patients with type 2 diabetes.
Methods
Study design
This was a 12-week single-arm pilot study to assess the 
effects of luseogliflozin on EFV in patients with type 2 
diabetes. This study was undertaken in accordance with 
the principles of the Declaration of Helsinki and has been 
approved by the ethical committee of Tokyo Medical and 
Dental University (No. 2102). This study was registered 
at the UMIN Clinical Trial Registry (UMIN000019072). 
All patients provided written informed consent before 
participation.
Subjects
We screened patients with type 2 diabetes aged older 
than 20  years who regularly visited the Tokyo Medi-
cal and Dental University Hospital. The inclusion crite-
ria were as the followings: (1) type 2 diabetes diagnosed 
according to the criteria of the Japan Diabetes Society 
(JDS) [25], (2) a BMI equal to or greater than 25 kg/m2, 
(3) HbA1c levels between 6.5 and 9.0%. Exclusion criteria 
were: (1) type 1 diabetes, (2) any history of taking SGLT2 
inhibitors, (3) insulin treatment, (4) severe renal or liver 
disease, (5) malignant neoplasm, (6) pregnant women, (7) 
any history of acute coronary syndrome or stroke within 
3  months prior to the enrollment, (8) patients whose 
treatment for diabetes were changed 3  months prior to 
baseline evaluation, (9) those who had contraindications 
for magnetic resonance imaging (MRI).
Intervention
Luseogliflozin was administered from 2.5  mg once 
daily after breakfast and the dosage was allowed to be 
increased up to 5.0  mg if HbA1c kept more than 7.0% 
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by 2.5  mg of luseogliflozin. During the 12  weeks, anti-
hyperglycemic agents other than luseogliflozin were 
unchanged, except when unacceptable hyperglycemia, 
hypoglycemia, or adverse events (AEs) occurred. The 
diet/exercise therapy and the combination anti-hypergly-
cemic agents were to be continued unchanged from the 
baseline until the end of the study.
Clinical and biochemical analysis
Blood samples were collected at an overnight fasting 
state. HbA1c was measured using the latex agglutination 
method. HbA1c levels were expressed in accordance with 
the National Glycohemoglobin Standardization Programs 
recommended by the Japanese Diabetes Society [25]. The 
insulin sensitivity was assessed by a homeostasis model 
assessment as an index of insulin resistance (HOMA-IR) 
in patients whose fasting plasma glucose levels were less 
than 7.8  mmol/l. The systolic and diastolic blood pres-
sures (SBP and DBP) were measured in a sitting position 
after at least 5 min rest, using an electronic sphygmoma-
nometer (ES-H55, Terumo Inc., Tokyo, Japan). The BMI 
was calculated as the weight divided by the square of the 
height (kg/m2). Routine tests included alanine transami-
nase (ALT), aspartate transaminase (AST), gamma-glu-
tamyl transpeptidase (γ-GTP), high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) cholesterol, 
triglycerides, uric acid, C-reactive protein, hemoglobin, 
and hematocrit. All tests were determined using standard 
laboratory procedures. Urinary albumin and creatinine 
excretion were measured in a spot urine collection by a 
turbidimetric immunoassay and enzymatic method. The 
ratio (ACR, mg/g) was used for the assessment of albumi-
nuria. The GFR was calculated using the following equa-
tion for the Japanese [26]; GFR = 194 × SCr−1.094 × age−
0.287 [(if female) × 0.739], where SCr (mg⁄dl) is measured 
by an enzymatic method. Adiponectin, leptin and inter-
leukin 6 (IL-6) were measured using latex turbidimetric 
immunoassay, double-antibody radioimmunoassay, and 
chemiluminescent enzyme immunoassay, respectively.
Quantification of abdominal adiposity, hepatic fat 
accumulation by CT
Both visceral fat area (VFA) and subcutaneous fat area 
(SFA) were measured at the level of umbilicus by the 
abdominal computed tomography (CT) examination 
(Aquilion PRIME, Toshiba Medical Systems, Tochigi, 
Japan) as described previously [27]. The hepatic fat accu-
mulation was also determined by the liver attenuation 
index (LAI) in the CT examination as described previ-
ously [28]. The LAI was calculated as follows: the average 
attenuation value of the liver (eight points) divided by the 
average attenuation value of the spleen (three points).
Body composition measured by DXA
The regional fat and fat-free mass were measured using 
the whole body DXA (Lunar iDXA, GE Healthcare, Mad-
ison, WI, USA) as described previously [27]. The skeletal 
muscle index (SMI) was calculated as the appendicular 
non-fat mass divided by the square of the height (kg/m2). 
The body fat (%) was calculated as the whole body fat 
mass divided by the body weight.
Quantification of epicardial fat volume by MRI
The EFV was measured using 1.5T-MRI system (Achieva 
Dual, Philips Healthcare, Netherland or Titan, Toshiba 
Medical Systems, Japan) with a 32-channel commercially 
available cardiac coil and was assessed using a modified 
fat excitation based on the whole-heart coronary MR 
angiography sequence [29]. A patient-specific acquisi-
tion window was set during either systole or diastole, 
depending on the phase of minimal motion of the right 
coronary artery. Typical parameters of the sequence 
included repetition time, 3.2 ms; echo time, 1.6 ms; flip 
angle, 15°; sensitivity-encoding factor, 2.5; field of view, 
330  ×  330  ×  128  mm; acquisition matrix, 248  ×  238; 
acquired spatial resolution, 1.3  ×  1.4  ×  1.6  mm, and 
reconstructed voxel size, 0.64  ×  0.64  ×  0.8  mm. All 
MR mages were transferred to a workstation (Ziosta-
tion 2, Japan). Semiautomatic analyses of EFV were per-
formed by an experienced operator blinded to the clinical 
information.
Study endpoints
The primary endpoint of this study was the decrease 
in EFV at 12  weeks. The secondary endpoints were the 
losses in the following variables at 12 weeks: VFA, SFA, 
SMI, LAI, HbA1c, HOMA-IR, blood pressure, lipid pro-
file, albuminuria, C-reactive protein (CRP), adiponectin, 
leptin, and IL-6. We further determined the impact of 
luseogliflozin on the EFV and VFA levels normalized by 
the body surface area (BSA) using the ratios of the EFV 
and VFA divided by the BSA (EFV/BSA ratio and VFA/
BSA ratio).
Statistical analysis
Statistical analysis was carried out using a IBM SPSS 
version 21.0 statistical package (IBM Corp. Released 
2012. IBM SPSS Statistics for Windows, Version 21.0. 
Armonk, NY: IBM Corp.). Data are presented as the 
mean  ±  standard deviation (SD) or standard error of 
mean (SE), median with interquartile range (IQR), or 
percent as appropriate according to the data distribu-
tion. Pearson product-moment correlation analysis was 
used to investigate the correlation of EFV with the mark-
ers for body composition and cardio-metabolic risks. 
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The primary endpoint was analyzed using the Wilcoxon 
signed-rank test. The secondary endpoints were also ana-
lyzed by paired t test or Wilcoxon signed-rank test. p val-
ues <0.05 were considered to be statistically significant.
Results
Demographics
Twenty patients were recruited and inform consent was 
obtained from all subjects. At baseline, one patient was 
not eligible for the study because the HbA1c level was 
less than 6.5% and finally 19 patients (95.0%) completed 
the study. Table 1 presents the baseline demographic data 
and Table 2 shows the medications at baseline. Regarding 
the anti-diabetic medications, the patients were treated 
primarily with metformin and/or dipeptidyl peptidase 4 
(DPP4) inhibitors. Approximately one-third of the par-
ticipants were receiving calcium channel blockers, angi-
otensin receptor blockers, and anti-platelet agents and 
statins were prescribed to more than 50% of the patients.
Correlation of EFV with markers for body composition 
and cardio‑metabolic risks
As shown in Table 3, the EFV was significantly correlated 
with the BMI, VFA, total fat mass, and HOMA-IR and 
tended to be correlated with the SFA. In contrast, no sig-
nificant association was observed between the EFV and 
the markers for cardio-metabolic risks, hepatic steatosis, 
adipokines, and SMI.
Efficacy and safety
As shown in Table  1, luseogliflozin treatment signifi-
cantly reduced the EFV at 12 weeks; whereas, the hepatic 
fat accumulation (LAI) kept unchanged by luseogliflo-
zin. Among markers for body composition, body fat (%), 
total fat and non-fat mass, non-fat mass in the upper 
and the lower extremities, and the appendicular SMI, 
all of which were measured using the whole body DXA, 
were significantly decreased by luseogliflozin. In con-
trast, neither VFA nor SFA, measured by abdominal CT 
were unchanged by luseogliflozin at 12  weeks. When 
EFV and VFA were normalized by the BSA (EFV/BSA 
ratio and VFA/BSA ratio), the significant impact of luse-
ogliflozin on the decline of EFV was slightly attenuated 
[58.4 (50.7–70.0) cm3/m2 at baseline to 57.2 (46.5–68.5) 
cm3/m2 at 12  weeks, p  =  0.064] and luseogliflozin did 
not reduce the VFA/BSA ratio [89.1 (61.4–106.2) cm2/
m2 at baseline to 86.7 (70.1–103.5) cm2/m2 at 12 weeks, 
p  =  0.619]. Among the cardio-metabolic risk factors, 
fasting plasma glucose, insulin, and HbA1c levels were 
significantly reduced by luseogliflozin. The insulin sensi-
tivity, assessed by HOMA-IR, was significantly improved 
Table 1 Clinical characteristics at baseline and at 12 weeks 
after  the administration of  luseogliflozin in  patients 
with type 2 diabetes
ACR albumin-to-creatinine ratio, ALT alanine transaminase, AST aspartate 
transaminase, CRP C-reactive protein, DBP diastolic blood pressure, 
EFV epicardial fat volume, GFR glomerular filtration ratio, GTP glutamyl 
transpeptidase, HDL high-density lipoprotein, HOMA-IR homeostasis model 
assessment as an index of insulin resistance, LDL low-density lipoprotein, SBP 
systolic blood pressure, SFA subcutaneous fat area, VFA, visceral fat area
Baseline 12 weeks p values
Age (years) 55 ± 12
Gender (% female) 26
SBP (mmHg) 137 ± 14 128 ± 15 0.035
DBP (mmHg) 83 ± 7 80 ± 7 0.023
Body weight (kg) 82.2 ± 11.4 79.5 ± 11.5 < 0.001
Body mass index (kg/m2) 28.7 ± 2.7 27.8 ± 2.9 < 0.001
Waist circumference (cm) 101 ± 8 99 ± 8 0.067
HbA1c (mmol/mol) 57.9 ± 5.4 50.9 ± 4.5 <0.001
HbA1c (%) 7.5 ± 0.7 6.8 ± 0.6 <0.001
Plasma glucose (mmol/l) 7.6 ± 2.2 6.8 ± 1.6 0.026
Insulin (μU/ml) 8.9 (5.3–13.6) 8.1 (4.7–11.7) 0.030
HOMA-IR (N = 15) 3.6 (1.5–4.8) 2.6 (1.3–3.8) 0.006
Triglycerides (mmol/l) 1.67 (1.15–2.85) 1.10 (0.93–2.39) 0.044
HDL cholesterol (mmol/l) 1.38 ± 0.36 1.36 ± 0.33 0.605
LDL cholesterol(mmol/l) 2.89 ± 0.51 3.02 ± 0.66 0.267
AST (U/l) 24 (18–40) 23 (17–28) 0.075
ALT (U/l) 19 (17–43) 23 (18–30) 0.407
γ-GTP (U/l) 35 (23–80) 28 (19–59) 0.088
Estimated GFR (ml/
min/1.73 m2)
69.7 ± 13.8 68.1 ± 13.3 0.407
Log urinary ACR (mg/g) 1.62 ± 0.55 1.56 ± 0.48 0.232
Uric acid (μmol/l) 351 ± 64 326 ± 91 0.107
Log CRP (mg/l) −0.01 ± 0.45 −0.10 ± 0.33 0.392
Hemoglobin (g/dl) 14.1 ± 3.3 15.3 ± 1.3 0.105
Hematocrit (%) 43.4 ± 3.1 45.7 ± 3.7 <0.001
Adiponectin (μg/ml) 8.8 ± 3.3 8.5 ± 3.4 0.233
Leptin (ng/ml) 13.9 ± 6.1 13.1 ± 6.8 0.377
Log Interleukin 6 (pg/ml) 0.30 ± 0.23 0.24 ± 0.26 0.278
EFV (cm3) 117 (96–136) 111 (88–134) 0.048
VFA (cm2) 167 (134–201) 151 (124–209) 0.811
SFA (cm2) 226 (184–273) 218 (178–240) 0.184
Liver attenuation index 1.03 ± 0.21 1.04 ± 0.22 0.670
Body fat (%) 36.9 ± 5.6 36.2 ± 6.0 0.027
Non-fat mass in upper 
extremities (kg)
5.7 ± 1.3 5.5 ± 1.3 0.012
Non-fat mass in lower 
extremities (kg)
16.8 ± 3.3 16.3 ± 3.4 0.012
Android (kg) 3.4 ± 1.4 2.9 ± 0.8 0.126
Gynoid (kg) 4.6 ± 1.8 3.8 ± 1.0 0.186
Total fat mass (kg) 29.3 ± 5.9 27.9 ± 6.3 <0.001
Total non-fat mass (kg) 50.4 ± 8.4 49.3 ± 8.4 0.003
Skeletal muscle index 7.81 ± 1.09 7.58 ± 1.11 0.004
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in patients whose fasting plasma glucose level was less 
than 7.8 mmol/l (N = 15). Significant reductions of both 
the systolic and diastolic blood pressures were observed 
by luseogliflozin. The triglycerides level was significantly 
reduced by luseogliflozin, whereas the HDL cholesterol 
level was unchanged. The adiponectin, leptin, and IL-6 
levels were unchanged by luseogliflozin. No severe AEs 
including severe hypoglycemic episodes were observed 
during the study period.
Correlation of changes in EFV, LAI, VFA, SFA with those 
in markers for body composition and cardio‑metabolic 
risks by luseogliflozin
Table 4 shows the correlation of the changes in EFV, LAI, 
VFA, and SFA with those in the markers for body com-
position, cardio-metabolic risks, and adipokines. The loss 
of EFV was significantly correlated with the reductions in 
both BMI and log CRP (Table 4). In contrast, the increase 
in LAI was significantly correlated with the decreases in 
VFA, body fat (%), and log CRP. Among adipokines, the 
decrease in leptin was significantly correlated with the 
decrease in VFA as was the increase in adiponectin with 
the reduction in SFA. However, neither the decrease in 
EFV nor the increase in LAI showed no significant asso-
ciation with the changes in adipokines.
Discussion
This single-arm pilot study demonstrates that luseogliflo-
zin treatment significantly reduces EFV in patients with 
type 2 diabetes and the reduction of EFV is associated 
with the improvement of micro-inflammation and the 
reduction of body weight. To the best of our knowledge, 
this is the first study to examine the effect of SGLT2 
inhibitors on EFV in patients with type 2 diabetes and 
the finding suggests the possibility that SGLT2 inhibitors 
may reduce cardiovascular, especially coronary artery 
events partly by reducing the EFV in patients with type 
2 diabetes.
EF accumulation has recently been reported to be 
associated with a non-calcified coronary plaque [7–9], 
cardio-metabolic risks including insulin resistance [10, 
11] and type 2 diabetes [12] and fatal and nonfatal coro-
nary events, independently of traditional cardiovascular 
risk factors [9]. These observations imply the presence 
of mechanisms that can account for the increased risks 
of coronary artery disease by an increase in EFV. Adi-
pokines and inflammatory cytokines secreted from EF 
are thought to physiologically regulate heart vessels, via 
paracrine and vasocrine mechanisms [30] and EF is rec-
ognized as an energy reservoir for resident cardiomyo-
cytes [31]. It is therefore conceivable that the reduction 
of EFV could be associated with reduced cardio-met-
abolic risks, presumably leading to the prevention of 
Table 2 Medications at baseline
ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin receptor 
blockers, DPP4 dipeptidyl peptidase 4, GIs glycosidase inhibitors, GLP1 glucagon-






DPP4 inhibitors (%) 63
GLP1 receptor agonists (%) 5
ACEIs (%) 5
ARBs (%) 37






Anti-platelet agents (%) 32
Table 3 Correlation of epicardial fat with markers for body 
composition and  cardio-metabolic risks in  patients 
with type 2 diabetes
ACR albumin-to-creatinine ratio, ALT alanine transaminase, DBP diastolic 
blood pressure, HDL high-density lipoprotein, HOMA-IR homeostasis model 
assessment as an index of insulin resistance, SBP systolic blood pressure
r p values
Body composition markers
 Body weight (kg) 0.310 0.196
 Body mass index (kg/m2) 0.485 0.044
 Waist circumference (cm) 0.364 0.126
 Visceral fat area (cm2) 0.467 0.044
 Subcutaneous fat area (cm2) 0.452 0.052
 Liver attenuation index −0.210 0.388
 Body fat (%) 0.249 0.304
 Total fat mass (kg) 0.484 0.036
 Total non-fat mass (kg) 0.103 0.675
 Skeletal muscle index 0.233 0.337
Cardio-metabolic markers
 HbA1c (%) −0.312 0.193
 HOMA-IR 0.502 0.046
 Triglycerides (mmol/l) −0.100 0.684
 HDL cholesterol (mmol/l) −0.041 0.869
 SBP (mmHg) 0.073 0.765
 DBP (mmHg) 0.309 0.198
 ALT (U/l) 0.175 0.475
 Log CRP (mg/l) 0.130 0.608
 Log ACR (mg/g) −0.143 0.561
 Adiponectin (μg/ml) 0.159 0.608
 Leptin (ng/ml) −0.143 0.561
 Log interleukin 6 (pg/ml) 0.174 0.490
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future cardiovascular events, via the reduction of proin-
flammatory adipokines. In this study we were unable to 
see the significant changes in the levels of adipokines by 
luseogliflozin treatment. It may be due to the relatively 
small reduction of body fat including EFV by luseogliflo-
zin. Finally, luseogliflozin may have less of an impact on 
the circulatory levels of adipokines.
When considering the correlation between cardio-
metabolic risks and EFV at baseline, the EFV was signifi-
cantly correlated with the BMI, VFA, and HOMA-IR in 
this study. EF embryologically derives from the splanch-
nopleuric mesoderm [32], sharing an embryologic origin 
with the intra-abdominal visceral adipose tissue [33, 34]. 
Therefore, it may be acceptable that patients with a high 
EFV are at a high risk for the increased visceral adiposity, 
leading to the peripheral insulin resistance. Indeed, EFV 
was reported to be strongly correlated with VFA [35]. 
Given these findings, we believe that the statistical signif-
icance of EFV with other markers for adiposity or insulin 
resistance in this study can be considered as moderate 
(Pearson’s correlation coefficient were approximately 0.5), 
although the sample size of this study was small. In con-
trast, luseogliflozin treatment significantly reduced EFV 
but not VFA in the present study even though some pre-
vious studies demonstrated that SGLT2 inhibitors can 
reduce visceral adiposity [36, 37]. This unexpected result 
might be partially explained by the small sample size of 
this study. Additionally, it has been reported that the 
reduction of EFV was not correlated with that of VFA in 
severely obese patients with a rapid weight loss by bari-
atric surgery [38]. Therefore, further large-scale clinical 
studies are needed to elucidate the association between 
the reduction of EFV and that of VFA in case obese 
patients with diabetes lose weight. We also revealed that 
the reduction of EFV is associated with the reduction of 
CRP. Systemic micro-inflammation causes insulin resist-
ance and is located in the central of the initiation and the 
propagation of atherosclerosis [39]. It is therefore pos-
sible that luseogliflozin could reduce the risks for future 
cardiovascular events partially by the attenuation of sys-
temic micro-inflammation.
There is growing evidence that diabetic treatment can 
reduce the EFV in patients with diabetes. Sack et al. firstly 
showed that pioglitazone decreases a genetic expression 
of proinflammatory and anti-inflammatory cytokines 
in EF in patients with type 2 diabetes and coronary 
Table 4 Correlations of the changes between markers for body composition and the markers for cardio-metabolic risks 
in patients with type 2 diabetes
ACR albumin-to-creatinine ratio, ALT alanine transaminase, CRP C-reactive protein, DBP diastolic blood pressure, EFV epicardial fat volume, HDL high-density 
lipoprotein, HOMA-IR homeostasis model assessment as an index of insulin resistance, LAI liver attenuation index, SBP systolic blood pressure, SFA subcutaneous fat 
area, VFA visceral fat area
Delta EFV Delta LAI Delta VFA Delta SFA
r p values r p values r p values r p values
Changes in body composition markers
 Body weight (kg) 0.301 0.113 −0.616 0.003 0.686 0.001 0.250 0.159
 Body mass index (kg/m2) 0.387 0.046 −0.531 0.012 0.719 <0.001 0.292 0.120
 EFV NA 0.154 0.264 −0.237 0.164 −0.075 0.379
 LAI 0.154 0.264 NA −0.391 0.049 −0.168 0.245
 VFA (cm2) −0.237 0.164 −0.391 0.049 NA 0.272 0.130
 SFA (cm2) −0.075 0.379 −0.168 0.245 0.023 0.463 NA
 Body fat (%) 0.103 0.342 −0.468 0.025 0.296 0.117 −0.149 0.277
 Total fat mass (kg) 0.166 0.255 −0.723 <0.001 0.284 0.127 0.082 0.374
 Total non-fat mass (kg) −0.063 0.402 0.224 0.186 −0.255 0.154 −0.082 0.374
 Skeletal muscle index 0.187 0.229 −0.154 0.271 0.143 0.285 0.350 0.047
Changes in cardio-metabolic markers
 HbA1c (%) 0.256 0.152 −0.150 0.277 0.073 0.387 0.282 0.128
 HOMA-IR −0.271 0.155 0.315 0.118 0.306 0.117 0.094 0.364
 ALT (U/l) −0.044 0.490 −0.170 0.251 0.249 0.159 −0.203 0.210
 Log CRP (mg/l) 0.493 0.019 −0.453 0.029 −0.039 0.438 0.302 0.112
 Log ACR (mg/g) −0.069 0.393 0.042 0.434 0.333 0.048 −0.069 0.393
 Adiponectin (μg/ml) −0.228 0.189 0.154 0.264 −0.167 0.261 −0.571 0.008
 Leptin (ng/ml) 0.146 0.295 0.115 0.330 0.378 0.044 −0.138 0.305
 Log interleukin 6 (pg/ml) −0.411 0.064 −0.318 0.115 0.296 0.142 0.007 0.490
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artery disease [40]. More recently, Lima-Martínez et  al. 
reported that the addition of sitagliptin produced a sig-
nificant and rapid reduction of EFV in overweight/obese 
patients with type 2 diabetes who were inadequately con-
trolled on metformin monotherapy [41]. Iacobellis et al. 
also has demonstrated that liraglutide, glucagon-like pep-
tide 1 receptor agonist, has a similar effect of reducing 
the cardiac fat independently of the loss of body weight 
[42]. Therefore, we believe that the findings in the pre-
sent study expand evidence of therapeutic approach to 
preventing coronary artery disease by diabetic treatment 
aimed at the reduction of EFV.
In contrast to the favorable effects of luseogliflozin on 
the reduction of EFV and the improvement of glycemic 
control, we need to address the significant reduction of 
non-fat mass and SMI by luseogliflozin in this study. It is 
reasonable that SGLT2 inhibitors can be administered in 
patients who are expected to show the decrease in both 
visceral and ectopic fat including EFV and no loss of the 
muscle mass by these drugs. Unfortunately, luseogliflo-
zin reduced SMI in all patients in this study. Therefore 
we were unable to clarify the clinical features of patients 
who can be safely administered luseogliflozin from the 
perspective of muscle mass. A decrease in skeletal mus-
cle mass is a component of sarcopenia which is defined 
as the progressive loss of muscle mass and function with 
aging [43, 44]. Diabetes is a strong risk factor for both 
the decrease in muscle mass and the loss of muscle func-
tion [45, 46]. Therefore, to avoid the unfavorable decrease 
in muscle mass, the administration of SGLT2 inhibitors 
should be carefully considered in patients with diabetes 
who are at a high risk for sarcopenia, especially in elderly 
patients with diabetes. Resistance training is reported to 
be associated with the attenuation of a rapid decline of 
muscle mass in elderly patients with diabetes [47]. It is 
therefore expected in the future studies that the combi-
nation of SGLT2 inhibitors and resistance training could 
be feasible and effective to preserve the muscle mass and 
function in patients with diabetes.
Potential limitations of our study are as follows: (1) 
this study is a single-arm pilot study and the sample size 
is small. Therefore, larger randomized control trials are 
needed; (2) no information is available regarding the diet 
and exercise which could influence not only the glycemic 
control but also the changes in body composition includ-
ing EFV; (3) it is to be elucidated whether the findings 
in this study could be observed in non-obese patients 
with type 2 diabetes; (4) it is important to investigate 
whether the reduction of EFV could be associated with 
the improvement of cardiovascular function; however, we 
were unable to examine the change of parameters related 
to cardiovascular function, such as diastolic function or 
pulse wave velocity in this study; (5) we need to mention 
the absolute reduction of EFV by luseogliflozin. Luse-
ogliflozin reduced EFV by 6 cm3 (5.1% reduction relative 
to the baseline value) in this study. EFV has been reported 
to be robustly reduced from 137 ± 37 cm3 to 98 ± 25 cm3 
with decreases in BMI (43.1 ± 4.5 kg/m2 to 32.3 ± 4.0 kg/
m2) or VFA (190 ± 83 cm2 to 107 ± 44 cm2) by bariat-
ric surgery in severely obese patients [38]. Therefore, in 
order to avoid an exaggerated expectation about the clin-
ical use of luseogliflozin, we would like to emphasize that 
luseogliflozin may have a significant but relatively weak 
impact on the reduction of EFV as well as that of VFA or 
body weight compared to bariatric surgery.
In summary, our data suggest that luseogliflozin could 
reduce EFV in parallel with the improvement of systemic 
micro-inflammation and the reduction of body weight 
in Japanese patients with type 2 diabetes. It may be nec-
essary to pay close attention to the potential of SGLT2 
inhibitors to decrease the skeletal muscle mass.
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